Received Aug 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | U8493AA | OT |
| MMR | MEASLES + MUMPS + RUBELLA (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | OT |
A patient was supposed to receive an MMR vaccine. Instead of using the correct diluent for the MMR vaccine, a medical assistant reconstituted the MMR dose with MenQuadfi with no reported adverse event; Initial information received on 05-Aug-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 65 years old male patient who was supposed to receive measles vaccine, mumps vaccine, rubella vaccine [MMR], instead of using the correct diluent for the MMR vaccine, a medical assistant reconstituted the MMR dose with meningococcal A-C-Y-W135 (T CONJ) vaccine [Menquadfi] with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 05-Aug-2025, the patient was supposed to receive an unknown dose of MMR not produced by Sanofi Pasteur (formulation, strength, expiry date and lot number not reported instead of using the correct diluent for the MMR vaccine, a medical assistant reconstituted the MMR dose with an unknown dose of meningococcal A-C-Y-W135 (T CONJ) vaccine Solution for injection (strength- unknown, expiry date- 31-MAY-2028 and lot U8493AA) via intramuscular route in unknown administration site for prophylactic vaccination (Immunization) with no reported adverse event (wrong product administered) (latency- same day). Reportedly, the patient was not supposed to get MenQuadfi at all. No other immunizations were there. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.